Company news
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) news
Phathom Pharmaceuticals, Inc. news releases on 6ix. Latest, May 15, 2024: Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual…
Press releases — page 2
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
May 14, 2024
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 8, 2024
Phathom Pharmaceuticals to Report First Quarter 2024 Financial Results and Provide Business Update on Thursday, May 9, 2024
April 28, 2024
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 2, 2024
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
March 25, 2024
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 6, 2024
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
February 28, 2024
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
February 12, 2024
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 30, 2024
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
December 13, 2023
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
December 5, 2023
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
November 27, 2023
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
November 8, 2023
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
October 31, 2023
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
October 29, 2023
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
September 25, 2023
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
August 20, 2023
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
August 9, 2023
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
June 11, 2023
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
June 8, 2023
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
May 22, 2023
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 22, 2023
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
May 22, 2023
Phathom Pharmaceuticals Reports First Quarter 2023 Results
May 9, 2023
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
May 8, 2023
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
April 3, 2023
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023
Phathom Pharmaceuticals Provides Regulatory Updates
February 8, 2023
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
January 7, 2023
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
January 2, 2023
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 7, 2022
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
November 2, 2022
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing Agreement
October 31, 2022
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)
October 23, 2022
Phathom Pharmaceuticals Presents New Data Evaluating First-in-Class Potassium-Competitive Acid Blocker (PCAB) Vonoprazan as Novel On-Demand Treatment in NERD at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 22, 2022
Phathom Pharmaceuticals to Present Latest Data on Vonoprazan at American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
October 17, 2022
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
September 25, 2022
Phathom Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Phathom Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 1, 2022
Phathom Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
May 31, 2022
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
May 24, 2022
Phathom Pharmaceuticals Presents Data on Novel Potassium-Competitive Acid Blocker (PCAB) Vonoprazan from a Range of Studies at Digestive Disease Week® (DDW) 2022
May 23, 2022
Phathom Pharmaceuticals to Present Data at DDW 2022 Annual Meeting
May 16, 2022
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 9, 2022
Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital
May 3, 2022
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
May 2, 2022
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
April 25, 2022
Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
March 31, 2022
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
March 21, 2022
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
March 13, 2022